Four countries will climb the global R&D rankings by 2028, and Taiwan is on track to overtake France, according to a new analysis of national research spending.

The projection lands in a ranking that has already lost its long-standing stability. For years, the order of countries spending the most on research held roughly constant: the United States first, China second, with Germany, Japan and South Korea filling out the next tier. That hierarchy has now broken, with China taking the top spot when spending is measured on a purchasing power parity basis.

The shift matters for R&D managers reading the numbers, because the choice of currency adjustment is doing real work here. On nominal exchange-rate terms, the U.S. retains its lead. On a PPP basis, which adjusts for the fact that a researcher's salary, a laboratory lease or a piece of capital equipment costs less in Beijing than in Boston, China now outspends the United States. Any portfolio decision built around "where is the money" depends on which of those two yardsticks a team uses — and on recognizing that PPP-based comparisons grow more favorable to lower-cost research economies almost automatically as cost differentials persist.

For organizations allocating research budgets internationally, the message is that the geography of aggregate R&D investment is moving faster than the legacy mental model. Taiwan's projected rise past France — and the climb of three other countries in the rankings through 2028 — signals that mid-tier economies are compounding research investment at rates the traditional R&D powers are not matching. France's position, long secure within the European research bloc's second rank behind Germany, now faces competition from an economy whose semiconductor-linked research base converts industrial strategy into R&D spending at scale.

The previous stability of the ranking reflected decades of aligned incentives: American federal and corporate research budgets set the ceiling, Japanese and German industrial R&D defined the second tier, and the tigers of East Korea and Taiwan grew into it. What has changed is not just scale but trajectory. Once a ranking begins to reorder at the top — as it has with China's move past the U.S. on PPP measures — the middle of the table rarely stays fixed for long, and the 2028 projections for Taiwan and the other climbers extend that logic.

R&D leaders should treat these projections with the same scrutiny they would apply to any vendor forecast. Ranking shifts of this kind depend on assumptions about exchange rates, inflation differentials and the trajectory of government research appropriations — all of which can move independently of actual laboratory output. A country can climb a PPP-adjusted spending table without a proportional gain in scientific capability if cost structures shift, and conversely, efficient research systems can deliver more publication, patent and product value per dollar than raw spending figures imply. The underlying analysis does not, from the available material, break out how much of each country's projected movement comes from real budget growth versus currency and price-level effects — a distinction that matters for anyone using these rankings to site facilities or form research partnerships.

What the numbers do establish is direction. The top of the table has already flipped on one standard measure, and the next four years are projected to bring further reordering through the middle ranks, with Taiwan passing France as one concrete marker. Organizations that built international research strategies on the assumption of a stable American-led hierarchy are working from an outdated map.

The full ranking and projections run to 2028 are detailed in the original analysis.